Smith+Nephew launches LYNX Laryngeal Wand
Analysis based on 6 articles · First reported Jul 15, 2026 · Last updated Jul 15, 2026
The launch is a routine product introduction with limited immediate market impact. It may strengthen Smith+Nephew's position in the ENT surgical device market but is unlikely to significantly affect the company's stock price or broader markets.
Smith+Nephew, a global medical technology company, announced the commercial launch of its LYNX COBLATION Laryngeal Wand, a multi-purpose surgical device designed for ENT airway procedures. The wand features a long working length, fine dissection and mass debulking capabilities, self-clearing clog technology, and a malleable shaft. It utilizes Smith+Nephew's patented COBLATION Technology, which has over 20 years of clinical use. The product was developed based on surgeon insights and received positive early feedback from Dr. Priya Krishna of Loma Linda University Health System. The launch is part of Smith+Nephew's ENT portfolio expansion.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard